Clinical Trial

Effectiveness of PGx Testing

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 2, 2024 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to determine the clinical and economic effectiveness of a pharmacogenomic (PGx) approach to prescribing medications in patients with high-risk polypharmacy in an integrated healthcare delivery system. Investigators hypothesize that patients who receive the RightMed® PGx test from OneOme, LLC with subsequent counseling of their prescribers by a study pharmacist, as needed, on the appropriateness of their prescribed medications will experience lower one-year follow-up healthcare utilization and expenditures compared to control patients who receive usual care.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2019-10-07; most recent amendment 2024-08-01.
Status change: Recruiting → Active, Not Recruiting 2022-03-15
Status change: Not Yet Recruiting → Recruiting 2020-01-27
Trial Details
NCT Number NCT04120480
Lead Sponsor Kaiser Permanente
Collaborators: OneOme, LLC
Conditions Polypharmacy
Enrollment 600 participants
Start Date 2019-11-15
Primary Completion 2026-06-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-08-02